NCT01341184View on ClinicalTrials.gov

TMC207 +/- Rifabutin/Rifampin

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

May 23, 2012

Study Completion Date

May 23, 2012

Conditions
Tuberculosis
Interventions
DRUG

Rifabutin

Rifabutin 300 mg orally on days 20-41

DRUG

Rifampin

Rifampin 600 mg orally on days 20-41

DRUG

TMC207

TMC207 400 mg orally on days 1 and 29

Trial Locations (1)

44106-1716

Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01341184 - TMC207 +/- Rifabutin/Rifampin | Biotech Hunter | Biotech Hunter